Friday, 13th November Clinical Oncology Society of Australia Annual Scientific Meeting 2020

Description: Quality of life (QoL) can be an aspect of cancer treatment that is often missed as there are no medical instrument to accurately measure such the QoL of treatment. In this symposium, we want to explore evidence behind Patient Reported Outcomes (PROs) and how it might affect the patient experience, in a prostate cancer perspective.

Chairs: A/Prof Arun Azard, Peter Maccallum Cancer Centre, Melbourne

Speakers:
A/Prof Alicia Morgan, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
Daniel Khalaf, BC Cancer Agency, Vancouver

This morning symposium is sponsored by Janssen.

Description: Melanoma is currently the 3rd most common cancer in both men and women in Australia. With this trend, it is important that the landscape of treatment options evolve to combat this. In this session, we will explore the melanoma patient trends of today and where they might head. We will also look at the data of current available therapies in BRAF-mutant metastatic melanoma, with a focus on newcomer BRAFTOVI® + MEKTOVI®, a BRAF/MEK inhibitor combination that was PBS listed in April 2020.

Chairs: Prof Mark Smithers, Surgeon, Director, Upper GI and Soft Tissue Unit, Chairman Queensland Melanoma Project, Princess Alexandra Hospital

Speakers:
Prof David Whiteman, Medical Epidemiologist, QIMR Berghofer
A/Prof Victoria Atkinson, Medical Oncologist, Princess Alexandra Hospital, Greenslopes Private Hospital
Dr Fiona Paxton-Hall, Medical Oncology Advanced Trainee, Princess Alexandra Hospital

This morning symposium is sponsored by Pierre Fabre Australia.

• Introduction  - Melvin Chua
• AI-powered Precision Diagnostics to Guide Cancer Treatment - Brandon Suh
• Artificial Intelligence for Consultation - The virtual MDT - David Cavallucci
• Artificial Intelligence for Imaging  - Gregory Sorensen
• Artificial Intelligence for Practice - Melvin Chua
• Putting a handbrake on the breakthrough: reflecting on the purpose, implementation and implications of artificial intelligence in healthcare - Stacy Carter

10:05 AM Panel Discussion

• Developing a Predictive Model utilising Real-world Pancreatic Cancer data and CT-based Radiomics for Implementation into Clinical Practice - Sam Banks
• Hereditary Cancer Whole Genome Sequencing Project to Identify Pathogenic Germline Variants - Aimee L Davidson
• Patient preferences regarding oral anti-cancer therapy: a systematic review. - Amy Davies
• Taxane-induced peripheral neuropathy: how serious is this problem for patients with early breast cancer? A single-centre series review - Robert Nicolae
• The effect of aerobic exercise on tumour blood delivery: a systematic review of preclinical and clinical studies - Catherine Seet-Lee

• Exercise to best support the body’s immune response to cancer – could intensity be key? - Marika E Carr
• Supportive care- Insights from a cancer patient experience survey - Spiridoula Galetakis
• An individualised, supervised exercise program is safe and feasible for patients with multiple myeloma: the MyeEx Study - Jennifer L Nicol
• Safety, feasibility and effect of exercise following cancer: do findings differ according to survival prospects? - Ben Singh

• Documentation of Symptoms in Children Newly Diagnosed With Cancer Highlights the Need for Routine Assessment Using Self-report - Natalie Bradford
• ‘Real-time’ collection and use of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs) in outpatient oncology: barriers, enablers, and impact on consultation length. - Olivia Cook
• Quality of life, functioning and emotional distress in survivors of human papillomavirus associated oropharyngeal cancer - Lachlan McDowell
• Exploring advance care planning awareness, experiences and preferences of people with cancer and support people: an Australian online cross-sectional study - Helena Rodi
• Exploring the profile of baseline patient-reported outcome measures and patient-reported experience measures in an outpatient oncology setting - Kate Webber

• COVID-19 international response: Reflections on the speed with which agencies were able to respond and build real-time data systems, the role of regional data warehouses and cross-sector collaboration, and how the data were used - Nigel McMillan
• Cancer in Australia – using the pandemic to improve cancer outcomes  - Dorothy Keefe
• Access and use of real-world data for cancer care and research: barriers and benefits - Kees Van Gool
• Modelling the impact of COVID-19 on cancer  - Karen Canfell

12:35 PM Panel Discussion 

• Financial toxicity - State of Science, Gaps and What's Next? - Louisa Gordon
• Informed Financial Consent: The Challenges to Implementation  - Sanchia Aranda
• The role of General Practitioners in addressing financial toxicity in cancer patients (FinTox-GP)   - Carla Thamm
• Financial toxicity – practical level interventions for patients and carers  - Michelle Bass

12:35 PM      Panel discussion

•  Implementation of smoking cessation programs in priority populations - Christine Paul
• Development and implementation of artificial intelligence and use of smart phone technology to achieve smoking cessation  - Henry Marshall
• Systematic review on smoking cessation implementation in cancer services   - Anna Ugalde

12:30 PM Panel Discussion with additional panel members: Cassandra Dickens & Amelia Lewis

• Lung cancer screening with a focus on implementation science  - Kwun Fong
• Implementing a clinical pathway for cancer-related anxiety and depression in 12 NSW Oncology services: Lessons learned  - Phyllis Butow
• Translating research into practice: outcomes from the healthy living after cancer partnership project  - Elizabeth Eakin
• Using PROs to screen for unmet needs in cancer in Australia  - Bogda Koczwara

• Cancer Immunotherapy – what have we learnt since the time of Coley? - Ian Frazer